REGULUS: MRI-guided Adaptive SABR for Liver Cancers

This study is testing a new way to deliver radiation therapy called MRI-guided adaptive stereotactic ablative body radiotherapy (SABR) for people with liver cancer, intrahepatic cholangiocarcinoma, or liver metastases. This treatment uses an MRI machine to guide the radiation and adjust the plan daily to precisely target the tumor. The study aims to see how many people are still alive one year after receiving this treatment. You may be able to join if you are 18 years or older and have a confirmed diagnosis of one of these liver cancers. The current recruitment status is unclear.

Study design: This is a single-arm study, meaning all 62 participants will receive the same treatment. It is unblinded, so both you and your doctors will know what treatment you are receiving.
What's involved: You will receive a single session of MRI-guided adaptive stereotactic ablative body radiotherapy (SABR). This treatment includes daily MRI imaging to update the radiation plan.
Compensation: Not stated in the trial record.
Follow-up: Your overall survival will be measured one year after receiving the SABR treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

REGULUS: MRI-guided Adaptive SABR for Liver Cancers

Recruiting

PHASE2Ages 18+InterventionalTreatment

Stanford University

~62 participants

Updated 2026-02-09 on ClinicalTrials.gov

What's tested:MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

1-year Overall Survival (OS)

Measured over 1 year after SABR

Conditions

Liver Cancer

Intrahepatic Cholangiocarcinoma

Liver Metastases

HCC

NCT07223307

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Stanford University
Palo Alto, Californiastudy coordinator listed
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Eleanor Brown

[email protected]

650-497-8966

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Histologically confirmed HCC, intrahepatic cholangiocarcinoma, or metastatic cancer. In the case of suspected HCC in patients with known cirrhosis, noninvasive criteria recommended by the European Association for the Study of Liver Diseases (lesion \> 1 cm with arterial phase hyperenhancement and venous phase washout) or LI-RADS score of 5 may be used

≥ 18 years old at time of study enrollment

Child-Pugh A status

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2

Life Expectancy \> 6 months

For women of childbearing potential or who are not postmenopausal (see Appendix F for Definition of Menopausal Status), a negative urine or serum pregnancy test must be done.

Ability to understand and the willingness to provide written informed consent.

Patients treated with prior liver-directed therapies with the exception of radioembolization are eligible for this study if they otherwise meet eligibility criteria

Exclusion

Prior treatment with radioembolization

Cytotoxic chemotherapy or investigational agent within 1 week of SABR

Prior radiotherapy overlapping with study treatment site

Female patients who are pregnant

Contraindication to having an MRI scan or inability to tolerate MRI

Presence of a pacemaker or other implanted cardiac device

Direct tumor extension into the stomach, duodenum, small bowel or large bowel

Patient unable to breath hold \> 15 seconds

What this trial measures

1-year Overall Survival (OS)1 year after SABR
Overall survival will be defined as the time from treatment to death from any cause. Patients alive at the time of analysis will be censored at last follow-up.

Trialytics